J P Morgan Chase & Co initiated coverage on shares of Sienna Biopharm (NASDAQ:SNNA) in a report published on Monday, MarketBeat reports. The firm issued an overweight rating and a $28.00 price target on the stock.
Separately, BMO Capital Markets started coverage on Sienna Biopharm in a research report on Monday. They issued an outperform rating and a $30.00 price objective for the company.
Sienna Biopharm (NASDAQ SNNA) opened at 23.87 on Monday. Sienna Biopharm has a 52 week low of $18.50 and a 52 week high of $26.45. The firm has a 50-day moving average of $20.25 and a 200 day moving average of $20.25.
In related news, CFO Richard D. Peterson bought 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average price of $15.00 per share, for a total transaction of $105,000.00. Following the transaction, the chief financial officer now directly owns 7,000 shares of the company’s stock, valued at $105,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Timothy K. Andrews bought 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were bought at an average price of $15.00 per share, with a total value of $225,000.00. Following the transaction, the general counsel now directly owns 51,737 shares in the company, valued at $776,055. The disclosure for this purchase can be found here. Insiders acquired a total of 48,700 shares of company stock valued at $730,500 in the last quarter.
About Sienna Biopharm
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
